Intravitreous Ranibizumab Cost-Effective for Some Patients With Proliferative Diabetic Retinopathy

Source: Medscape

Monday, May 15, 2017 | Medical Studies , Retina


Intravitreous ranibizumab appears to be cost-effective in patients with proliferative diabetic retinopathy (PDR) who have vision-impairing diabetic macular edema (DME), according to data from the Diabetic Retinopathy Clinical Research Network (DRCR.net). Panretinal photocoagulation (PRP) has long been the standard of care for treating most eyes with PDR, but it can cause peripheral vision loss and exacerbate DME. Intravitreous ranibizumab is also effective, but much more expensive than PRP, at around $2,000 per treatment versus around $345 for PRP.

Open in New Window

Comments

You must be logged in to leave a comment.